With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.

Projects from Affini-T, Bolt, Chimeric and Alentis, all hitting novel targets, as well as one from A2 using an old one, are set for first clinical trial entry.

Front-line phase 3 plans take shape, as the company claims a new success, this time in pancreatic cancer.

The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.